Natural Capsules Limited (IN:NATCAPSUQ)
:NATCAPSUQ
Want to see IN:NATCAPSUQ full AI Analyst Report?
NATCAPSUQ Stock Chart & Stats
₹166.70
--
Market closed
₹166.70
--
Day’s Range― - ―
52-Week Range₹137.50 - ₹296.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)8.08K
Market Cap
₹1.67B
Enterprise Value₹2.68B
Total Cash (Recent Filing)₹53.75M
Total Debt (Recent Filing)₹1.12B
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.25
Shares Outstanding10,411,154
10 Day Avg. Volume870
30 Day Avg. Volume8,081
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.47
Price to Sales (P/S)0.55
P/FCF Ratio-9.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth in FY2026 indicates underlying demand for the company’s products and provides a base for operating leverage recovery. Over months, higher top-line can fund margin improvement initiatives, product investment and rebuild cash generation if cost structure is managed.
Moderate LeverageDebt around half of equity implies the balance sheet retains room to absorb losses or fund operations without immediate refinancing stress. This moderate leverage gives flexibility to manage working capital and support near-term investments while pursuing operational fixes over the next several months.
Defensive Industry ExposureOperating in specialty and generic pharmaceuticals implies structurally steady demand, recurring product cycles and regulatory barriers to entry. These industry characteristics support more predictable volumes and potential pricing resilience across a 2-6 month horizon versus cyclical sectors.
Bears Say
Profitability DeteriorationA sharp fall to a sizable net loss and materially compressed gross and operating margins indicate core profit drivers are weak. Persisting margin pressure undermines cash flow and ROE, requiring structural cost, pricing or mix changes to restore sustainable profitability over the medium term.
Weak Cash GenerationVery low operating cash flow and consecutive negative free cash flow raise funding risk and limit internal ability to fund capex or working capital. Over 2-6 months this increases reliance on external financing or asset sales, which can constrain strategic flexibility and growth execution.
Equity Decline And Negative ROEFalling equity and negative ROE reflect value destruction from recent losses and weaken capital cushions. If losses persist, leverage metrics and borrowing capacity worsen, restricting investment and making recovery initiatives harder to fund without dilutive or costly external capital.
Natural Capsules Limited News
NATCAPSUQ FAQ
What was Natural Capsules Limited’s price range in the past 12 months?
Natural Capsules Limited lowest stock price was ₹137.50 and its highest was ₹296.40 in the past 12 months.
What is Natural Capsules Limited’s market cap?
Natural Capsules Limited’s market cap is ₹1.67B.
When is Natural Capsules Limited’s upcoming earnings report date?
Natural Capsules Limited’s upcoming earnings report date is Aug 12, 2026 which is in 52 days.
How were Natural Capsules Limited’s earnings last quarter?
Natural Capsules Limited released its earnings results on May 27, 2026. The company reported -₹4.82 earnings per share for the quarter, missing the consensus estimate of N/A by -₹4.82.
Is Natural Capsules Limited overvalued?
According to Wall Street analysts Natural Capsules Limited’s price is currently Overvalued.
Does Natural Capsules Limited pay dividends?
Natural Capsules Limited pays a N/A dividend of ₹1 which represents an annual dividend yield of N/A. See more information on Natural Capsules Limited dividends here
What is Natural Capsules Limited’s EPS estimate?
Natural Capsules Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Natural Capsules Limited have?
Natural Capsules Limited has 10,411,154 shares outstanding.
What happened to Natural Capsules Limited’s price movement after its last earnings report?
Natural Capsules Limited reported an EPS of -₹4.82 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 12.198%.
Which hedge fund is a major shareholder of Natural Capsules Limited?
Currently, no hedge funds are holding shares in IN:NATCAPSUQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Natural Capsules Limited
Natural Capsules Ltd. specializes in the production and global distribution of hard gelatin and cellulose capsule shells, catering to markets in India and abroad. The company offers a comprehensive array of capsule types, including those guaranteed free from bovine spongiform encephalopathy (BSE) and transmissible spongiform encephalopathy (TSE), shiny, sodium lauryl sulfate (SLS)-free, and halal-certified gelatin variants. Their product line further extends to fast-release, printed gelatin/cellulose, vegetarian, and enteric capsule shells. Beyond manufacturing shells, Natural Capsules Ltd. is also involved in formulating various pharmaceutical products in capsule dosage forms. Established in 1993, the company is headquartered in Bengaluru, India.
Technical Analysis
Aarey Drugs & Pharmaceuticals Ltd.
―
Alpa Laboratories Limited
―
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Vaishali Pharma Ltd.
―